Cimzia news from FiercePharma
NewsUCB's Cimzia app gets data boost
Will rheumatoid arthritis patients soon spell relief C-I-M-Z-I-A? The UCB drug, an anti-TNF biologic, got the FDA nod for Crohn's disease treatment in April, and an app for an arthritis indication is Read more...
Quick Cimzia launch overjoys UCB
UCB Pharma was delirious with glee when it managed to launch its new TNF inhibitor Cimzia for Read more...
| Press ReleasesCimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Administered every four weeks, UCB's pegylated anti-TNFa offers new treatment option for patients with moderate to Read more... PRESS RELEASE: UCB Group Drug Cimzia Faces EU Delay, Shares Plunge UCB Group Drug Cimzia Faces EU Delay, Shares Plunge Brussels (BELGIUM), November 16, 2007 at 7:00 am CET - UCB announced today that it has been informed by the European Medicines Agency (EMEA) that Read more... |
Get more Cimzia coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends